Wet granulation, dry granulation and direct blending are the three most common granulation processes for solid dosage form production in the pharmaceutical industry for decades. However, each of the three mentioned process has its drawbacks, among which, the requirement of post-granulation operations is one of the major weakness.
For a drug substance administered via oral route, it should possess adequately aqueous solubility before passes through the gastrointestinal tract to complete the absorption, and then enters the blood steams for the pharmacological actions.
Oral solid dosage forms, mainly in the forms of tablets and capsules, still dominate the drug product market for their convenience to patients, not only for administration, but also safe and easy to compliance. In manufacturing of oral solid dosage forms, the flowability of active pharmaceutical ingredient (API), excipients used to formulate the API, and formulations play an important role, and should be assessed in the drug product development stage.
Moisture-activated dry granulation (MADG) is an economical and novel granulation process which only requires minor amount of liquid (1-5%) to trigger the agglomeration of particles, uses the high shear granulator to spread out the moisture and then form uniform granules without subsequent drying or milling process, which can save the cycle time tremendously.
Lipid-based formulation is proven to be one of the effective approaches to enhance solubility of poorly soluble drugs. At J-Star, our scientists are experienced in this solubilization method, and at the same time, applying it to liquid-filled capsules to simplify the process and stay away from the manufacturing issues of oral dosage forms.
Roller Compaction is one of best processing methods to improve the flowability of API. Comparatively, direct compression which skips the granulation step is more cost- effective. Our enabling technique scan significantly improve the API particles flowability, make it possible to replace roller compaction process with direct compression process, and deliver quality products while simplifying the process.
Many active pharmaceutical ingredients (API) exhibit deficient bulk powder properties such as poor flowability, low bulk density, high cohesion, etc.
Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving.
Many active pharmaceutical ingredients (API) exhibit deficient bulk powder properties such as poor flowability, low bulk density, high cohesion, etc.
Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving.